Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib
Laura Cesini(Policlinico Umberto I), Roberto Latagliata(Ospedale di Belcolle), Robin Foà(Sapienza University of Rome), Matteo Molica(Sapienza University of Rome), Daniela Diverio(Policlinico Umberto I), Gioia Colafigli(Policlinico Umberto I), Lorenzo Rizzo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Fulvio Massaro(Policlinico Umberto I), Emilia Scalzulli(Policlinico Umberto I), Federico Vozella(Campus Bio Medico University Hospital), Maria Cristina Scamuffa(Policlinico Umberto I), Ida Carmosino(Policlinico Umberto I), Maria Giovanna Loglisci(Policlinico Umberto I), Elena Mariggiò(Policlinico Umberto I), Marco Mancini(Radboud University Nijmegen), Massimo Breccia(Policlinico Umberto I), Daniela De Benedittis(Sapienza University of Rome), Sara Mohamed(Royal College of Surgeons in Ireland - Bahrain), Giuliana Alimena
Cited by 9
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity
|Cytokine|2015|505
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464